D
David R. Gandara
Researcher at University of California, Davis
Publications - 725
Citations - 45633
David R. Gandara is an academic researcher from University of California, Davis. The author has contributed to research in topics: Lung cancer & Cancer. The author has an hindex of 84, co-authored 685 publications receiving 40321 citations. Previous affiliations of David R. Gandara include National Institutes of Health & University of Texas MD Anderson Cancer Center.
Papers
More filters
Journal ArticleDOI
Challenges in Facing the Lung Cancer Epidemic and Treating Advanced Disease in Latin America.
Luis E. Raez,Edgardo S. Santos,Christian Rolfo,Gilberto Lopes,Carlos H. Barrios,Andrés F. Cardona,Luis Mas,Oscar Arrieta,Eduardo Richardet,Carlos Vallejos S,Ignacio I. Wistuba,David R. Gandara,Fred R. Hirsch +12 more
TL;DR: The current situation in the management of lung cancer in Latin America is reviewed, hoping that this initiative will help physicians, patient associations, industry, governments, and other stakeholders better face this epidemic in the near future.
Journal ArticleDOI
Atezolizumab versus chemotherapy in advanced or metastatic NSCLC with high blood-based tumor mutational burden: primary analysis of BFAST cohort C randomized phase 3 trial
Solange Peters,Rafal Dziadziuszko,Alessandro Morabito,Enriqueta Felip,Shirish M. Gadgeel,Parneet Cheema,Manuel Cobo,Z. Andric,Carlos H. Barrios,Masafumi Yamaguchi,Eric Dansin,Pongwut Danchaivijitr,Melissa Lynne Johnson,Silvia Novello,Michael S. Mathisen,S.M. Shagan,Erica B. Schleifman,Jin Wang,Mark Yan,Simonetta Mocci,D. Voong,David Fabrizio,David S. Shames,Todd Riehl,David R. Gandara,Tony Mok +25 more
TL;DR: In this article , the authors evaluated the safety and efficacy of first-line targeted therapies or immunotherapy in patients with unresectable Stage IIIB or IV advanced or metastatic non-small cell lung cancer who were selected for biomarker status using blood-based targeted next-generation sequencing.
Journal ArticleDOI
72 Multicenter trial of docetaxel (Taxotere) in platinum-treated non-small cell lung cancer (NSCLC): Confirmation of prolonged survival☆
David R. Gandara,Everett E. Vokes,Mark R. Green,Philip Bonomi,Russell F. DeVore,Robert L. Comis,David P. Carbone,Daniel D. Karp,Chandra P. Belani +8 more
Journal ArticleDOI
Impact of atezolizumab (atezo) treatment beyond disease progression (TBP) in advanced NSCLC: Results from the randomized phase III OAK study.
David R. Gandara,Joachim von Pawel,Richard Sullivan,Åslaug Helland,Ji-Youn Han,Santiago Ponce Aix,Achim Rittmeyer,Fabrice Barlesi,Toshio Kubo,Keunchil Park,Jerome H. Goldschmidt,M. Gandhi,Cindy Yun,Wei Yu,C. Matheny,Pei He,Alan Sandler,Marcus Ballinger,Louis Fehrenbacher +18 more
TL;DR: This data indicates that CIT can have a positive impact on OS that exceeds response rate or PFS effects, termed post progression prolongation of survival (PPPS), and this effect can also affect survival in animals with normal immune status.
Journal ArticleDOI
Phase II Randomized Study of Ramucirumab and Pembrolizumab Versus Standard of Care in Advanced Non–Small-Cell Lung Cancer Previously Treated With Immunotherapy—Lung-MAP S1800A
Karen L. Reckamp,Mary W. Redman,Konstantin H. Dragnev,Katherine Minichiello,Liza C. Villaruz,Bryan A. Faller,Tareq Al Baghdadi,Susan J. Hines,Leah Everhart,Louise Highleyman,Vassiliki A. Papadimitrakopoulou,David R. Gandara,Karen Kelly,Roy S. Herbst +13 more
TL;DR: This randomized phase II trial demonstrated significantly improved OS with RP compared with SOC in patients with advanced NSCLC previously treated with ICI and chemotherapy, and the safety was consistent with known toxicities of both drugs.